Sales have fallen and I guess even that big reward from Boston Scientific for 2 billion in 2010 was not enough to keep things rolling along here. Apparently the stent business is growing in other places and sales are down to 2.5 billion from 4 billion just a few years ago. Other companies have received FDA approval faster than what Cordis has been able to do. 
Where’s Some of the Focus for Johnson and Johnson Revenue Cycles – “Legally Patented Stent Wars”?
The number to be laid off was not given out but sales is one area that will be affected. I guess we still have plenty of stents to go around. BD
NEW YORK, Feb 10 (Reuters) - Johnson & Johnson said its Cordis medical devices unit, whose sales have fallen sharply in recent years due to waning demand for its Cypher heart stent, will lay off an unspecified number of salespeople and merge two separate sales forces within the division.
"This change resulted in the elimination of some positions in our U.S. field sales organization, (but) we are continuing to call on all current accounts," said J&J (JNJ.N) spokeswoman Sandra Pound, who declined to disclose the number of layoffs.
Separate cardiology and endovascular sales teams, beginning on Thursday, were merged into a single Cordis Vascular sales force, she said.
0 comments :
Post a Comment